Compare Davita Inc (DVA) vs Rocket Lab USA Inc (RKLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Rocket Lab USA Inc — how do they compare? Davita Inc trades at $179.26 (market cap $11.29B), while Rocket Lab USA Inc trades at $67.45 (market cap $43.74B). The key difference: Rocket Lab USA Inc is far larger — about 3.9× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Rocket Lab USA Inc for 29 Days on average.
| DVA | RKLB | |
|---|---|---|
Market Cap | $11.29B | $43.74B |
Volume | 582,204 | 22,892,581 |
Sector | Health | Industrials |
52-Week High | $240.96 | $150.23 |
52-Week Low | $103.87 | $39.48 |
Typical Hold Time | 113 Days | 29 Days |
Enterprise Value | $24.01B | $41.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
Rocket Lab (RKLB) trades at $67.47, down 6.19% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of -$198.21M in 2025, though revenue grew to $601.80M. Recent news highlights a record 20-launch deal with Synspective, expanding the backlog past 100 missions, providing a positive catalyst amid ongoing losses and high valuation multiples.
The outlook remains speculative; strong analyst consensus (76% buy ratings) and a $107 price target suggest long-term growth potential from launch demand, but profitability challenges, cash burn, and competitive pressure from SpaceX pose significant risks. Investment hinges on execution toward Neutron rocket commercialization and path to sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →
